Browsing by Author "Kaplan, Y"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Pediatric inverted papilloma of the middle ear: Case report and review of the literature
    Ulkumen, B; Kaplan, Y; Kiroglu, AF; Bayram, I
    Inverted papilloma of middle ear is a very rare clinical entity. It has been reported only in the adult population. We report a middle ear inverted papilloma in an 11-year-old male. To the best of our knowledge it is the first pediatric inverted papilloma of middle ear. The patient had a history of chronic suppurative otitis media and the lesion was found during preoperative evaluation for a tympanoplasty procedure. Total excision of the lesion and a tympanoplasty operation was accomplished. We reviewed the middle ear inverted papilloma cases regarding the age distribution, pathophysiology, treatment and prognosis. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Should a booster dose be administered in children after mass immunization for hepatitis B?
    Tosun, S; Deveci, S; Kaplan, Y; Kasirga, E
    Background: Hepatitis B virus infection is a global health problem and vaccine-preventable disease, but the duration of the effects of HBV vaccination in infants is unknown. Objectives: The aim of this trial, which comprised children who had received 3 doses as part of the universal HBV immunization program and no additional doses, was to investigate anti-HBs titers and HBsAg status after 9 years. Patients and Methods: We performed a descriptive, cross-sectional field research study. The study sample, based on sociodemographics and minimum seroprevalence, was analyzed based on 10.00% +/- 1.50 (95% confidence interval) (1150 individuals); trial was realized in a total of 1279 children (623 females and 656 males). Anti-HBs titers were measured by micro-EIA (Dia Sorin-Italy); titers <10 lU/mL were negative, 10-49 IU/mL were low-positive, and >50 IU/mL were high-positive. For anti-HBs titers below protective levels, HBsAg was measured by micro-EIA. Results: In approximately half of the children (48.5% in those living in semiurban areas and 42.3% in urban areas), antibody titers were below protective levels. Conclusions: Mass HBV vaccination, which was implemented in Turkey in 1998, significantly decreases HBsAg positivity in childhood. Nevertheless, it might be necessary to administer a booster dose after 8-9 years in children, especially those in low socioeconomic areas or in whom irregular/insufficient immunization is suspected. (C) 2011 Kowsar M.P.Co. All rights reserved.
  • No Thumbnail Available
    Item
    Investigation of Tetanus Antitoxin Titer Levels in People Over Forty Years of Age
    Tosun, S; Deveci, S; Yücetürk, M; Dönmez, AB; Kaplan, Y
    Objective: Tetanus is a disease that can be prevented with vaccination, but protective antitoxin titers decrease to undetectable levels with old age. The aim of this study is to evaluate tetanus antitoxin levels in individuals over 40 years of age and to investigate the vaccination and physical injury status via survey. Material and Methods: A total of 361 participants, 178 men and 183 women, were enrolled in the study and blood was drawn from each participant to measure tetanus antibody level by enzyme immunoassay (ETA) method. Results: Tetanus antibodies were undetectable in 55 male (30.9%) and 71 female patients (38.8%) at the end of the study. It was determined that tetanus antitoxin levels significantly decrease with age in both women and men especially after 50 years of age which is accepted as the limit age in which antibody is likely to be negative. Conclusion: In adult age group, booster vaccination for tetanus is recommended every 10 years in developing and developed countries, but this recommendation can not be put into practice as anticipated. Similarly in our country, vaccination of adult age group is not common and tetanus vaccine is not generally administered at every ten years. The results of this study show that one dose of tetanus vaccine should be administered at least to individuals over 50 years of age, and individuals who do not recall their vaccination history should be taken into a three-dose vaccination program.